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Background: Functional polymorphisms in the receptor for advanced glycation end-products (RAGE) gene
have been implicated in several vascular diseases. However, to date, no study investigated the association
of RAGE polymorphisms with heart failure (HF).
Objective: In this study we tested the hypothesis that the 63-bp insertion/deletion, the −374T>A
(rs1800624) and the−429T>C (rs1800625) polymorphisms in the RAGE gene might be associated with sus-
ceptibility to HF and could predict all-cause mortality in Brazilian outpatients with left ventricular systolic
dysfunction.
Methods: A total of 273 consecutive HF patients (196 Caucasian- and 77 African-Brazilians) and 334 healthy
blood donors (260 Caucasian- and 74 African-Brazilians) were enrolled in a tertiary care university hospital.
Genotyping of RAGE polymorphisms was done by polymerase chain reaction (PCR) or PCR followed by
enzyme restriction analysis.
Results: The allele, genotype and haplotype frequencies of −374T>A and −429T>C polymorphisms were
not signiﬁcantly different between HF patients and healthy blood donors in both ethnic groups. However,
among African-Brazilians, the frequency of carriership of the del allele was lower in HF patients than in
blood donors (2.6% vs 12.2%, respectively, p=0.008). Patients were followed-up for a median of 38 months
and the survival analysis did not reveal a consistent association between RAGE polymorphisms and all-cause
death in both ethnic groups.
Conclusion: The −374T>A and −429T>C polymorphisms in the RAGE gene were not associated with the
susceptibility and prognosis of HF. Notwithstanding, the 63-bp ins/del polymorphism might be involved in
the susceptibility to HF in African-Brazilians.© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Heart failure (HF) is a clinical syndrome that represents the end-
stage of several heart diseases and remains a major cause of morbidity
and mortality worldwide. Despite recent advances in its medical treat-
ment, mortality rates due to HF remain elevated (Davis et al., 2000;e; AGEs, advanced glycation
RAGE; esRAGE, endogenously
g equilibrium; OR, odds ratio;
AGE, soluble RAGE.
ão em Diagnóstico Genético e
. Farroupilha, 8001, Prédio 22,
1 3477 9219.
,
alaubert@gmail.com
andreia@gmail.com (A. Biolo),
ail.com (K.G. dos Santos).
lsevier OA license.Roger et al., 2011). Heart failure is a multifactorial disorder, having
clinical, environmental and genetic components. Thus, some common
gene variants could increase the risk of developing HF and others
couldmodify disease progression or response topharmacological therapy
(Dorn, 2011).
The receptor for advanced glycation end-products (RAGE) is amem-
ber of the immunoglobulin superfamily of cell surface proteins that
binds advanced glycation end-products (AGEs) and other molecules. It
is expressed at low levels in most adult tissues under physiological
conditions, but is overexpressed in the vessel wall at sites of vascular
pathology (Kalea et al., 2009). In particular, RAGE levels are higher in di-
abetic patients and animalmodels of diabetes than in their non-diabetic
counterparts (Kalea et al., 2009; Yan et al., 2009). Accumulating
experimental evidence has shown that the interaction of AGEs with
RAGE leads to activation of intracellular signaling, gene expression,
and production of proinﬂammatory cytokines and free radicals, thus
playing a central role in the pathogenesis of vascular and heart disease
(Park et al., 2011; Yan et al., 2009).
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splicing of the RAGE gene (endogenously secreted RAGE—esRAGE) and
proteolytic cleavage of membrane-bound RAGE (cleaved RAGE—cRAGE).
The ability of sRAGE to bind RAGE ligands suggests a cytoprotective action
against AGEs (Kalea et al., 2009). Two prospective studies showed that
high sRAGE circulating levels were associated with severity of disease
and predicted cardiac events in patients with HF, regardless of AGE
levels and other known prognostic parameters (Koyama et al., 2008;
Raposeiras-Roubín et al., 2011). Moreover, high sRAGE levels were also
associated with ischemic HF (Raposeiras-Roubín et al., 2010) and one
study has shown that cRAGE levels are increased while esRAGE levels
are decreased in patients with HF as compared to healthy controls
(Wang et al., 2011).
Three polymorphisms described in the promoter of RAGE gene, name-
ly, a 63-bp insertion/deletion spanning from−407 to−345 nucleotides,
the −374T>A (rs1800624) and the −429T>C (rs1800625) polymor-
phisms were shown to have a marked effect on in vitro transcriptional
activity. The−429C,−374A and 63-bp del alleles resulted in an increase
of gene expression of two-, three- and four-fold, respectively (Hudson et
al., 2001a). Since then, these polymorphisms were studied as potential
risk factors involved in the pathogenesis of heart diseases in several
populations (Aydoğan et al., 2012; Boiocchi et al., 2011; Falcone et al.,
2004, 2005, 2007, 2008; Hudson et al., 2001b; Kirbis et al., 2004; Lu et
al., 2008; Peng et al., 2009; Pettersson-Fernholm et al., 2003; Picheth et
al., 2007; Poon et al., 2010; Santos et al., 2005; Shim et al., 2007; Yoon
et al., 2007). In particular, the AA genotype of the −374T>A polymor-
phism was shown to be associated with a reduced risk of cardiovascular
disease (coronary heart disease, acute myocardial infarction, peripheral
vascular disease) (Pettersson-Fernholm et al., 2003), coronary artery dis-
ease (Falcone et al., 2004), ischemic heart disease (Santos et al., 2005),
restenosis after coronary stent implantation (Falcone et al., 2007), acute
myocardial infarction (Boiocchi et al., 2011), adverse cardiac events
(Falcone et al., 2008) and with less severe coronary artery disease
(Falcone et al., 2005; Picheth et al., 2007).
Although there are studies evidencing that sRAGE levels levels are
predictors of worse prognosis in HF patients (Koyama et al., 2008;
Raposeiras-Roubín et al., 2011) and that polymorphisms in the RAGE
gene might be associated with development and severity of cardiovas-
cular diseases (Boiocchi et al., 2011; Falcone et al., 2004, 2005, 2007,
2008; Pettersson-Fernholm et al., 2003; Picheth et al., 2007; Santos et
al., 2005), to our knowledge, no study investigated the role of RAGE
gene polymorphisms in the pathogenesis of HF. Therefore, in this
study we tested the hypothesis that three functional polymorphisms
in the RAGE gene promoter, namely, the 63-bp insertion/deletion,
−374T>A and −429T>C, might be associated with susceptibility
to HF and could predict all-cause mortality in Brazilian outpatients
with left ventricular systolic dysfunction.
2. Material and methods
2.1. Study population
A total of 273 consecutive HF patientswith systolic dysfunction (196
Caucasian-Brazilians and 77 African-Brazilians), diagnosed according to
the ACCF/AHA guidelines (Jessup et al., 2009), were recruited from the
Heart Failure and Transplant Outpatient Clinic of a tertiary care univer-
sity hospital in Porto Alegre, Brazil between July 2003 and November
2007. The inclusion criteria were age ≥18 years and left ventricular
ejection fraction b45%. All patients had HF of idiopathic, ischemic or
hypertensive etiology. Patients with HF due to obstructive, hypertro-
phic or other cardiomyopathies (such as chagasic and alcoholic) were
excluded from the study, as well as patients with other serious illnesses
or with reduced life expectancy. At baseline, patients underwent a com-
prehensive clinical and biochemical evaluation consisting of a physical
examination, assessment of echocardiographic parameters and labora-
tory tests. Diabetes was diagnosed according to the American DiabetesAssociation criteria (American Diabetes Association, 2008). Demo-
graphical, clinical and routine laboratory data were collected from all
patients using a structured data form.
We also evaluated a group of 334 presumably healthy controls (260
Caucasian-Brazilians and 74 African-Brazilians) composed by unrelated
blood donors enrolled at the Hemotherapy Center of the same hospital
at the same period as HF patients. Before blood donation, volunteers
who accepted to participate in the protocol underwent a systematic
interview to evaluate personal or family history of premature sudden
death or cardiovascular diseases, the presence of atherosclerotic risk
factors or any overt clinical disease. Thosewith a history of cardiovascu-
lar disease or related symptoms and thosewith a positive family history
of premature sudden death were excluded. No additional laboratory
data were collected from blood donors.
The ethnic classiﬁcation of all subjects was self-reported. The
study protocol was approved by the local institutional review board
and by the National Agency of Ethics in Research and conforms to
the principles outlined in the Declaration of Helsinki. All subjects pro-
vided written informed consent before enrollment.
2.2. Outcome assessment
The HF patients were followed-up in the outpatient clinic of our
institution. Vital status was determined using the last registry
assessed in the hospital's electronic database. Telephone contact
was attempted for all patients for whom no registry was found in
the four months prior to follow-up assessment. Death from any
cause was also veriﬁed through the State Death Certiﬁcate Database.
2.3. DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood according to a
salting out method as previously described (Lahiri and Nurnberger,
1991). RAGE genotypes were identiﬁed by polymerase chain reaction
followed by restriction fragment length polymorphism (PCR-RFLP)
analysis, as previously described for the −374T>A and −429T>C
polymorphisms (Hudson et al., 2001a). The ampliﬁed products digested
by TasI restriction enzyme (−374T>A polymorphism) were elec-
trophoresed on 8% polyacrylamide gels, stained with ethidium bromide
and visualized under ultraviolet light. The digested fragments with AluI
(−429T>C polymorphism) were separated by electrophoresis on 2%
agarose gels containing ethidium bromide and also visualized under
ultraviolet light. Both restriction enzymes were purchased from MBI
Fermentas (St. Leon-Rot., Germany).
The 63-bp insertion/deletion was detected by PCR using the
same primers and conditions as described before for the −374T>A
and −429T>C polymorphisms (Hudson et al., 2001a). The alleles
were identiﬁed according to the length of bands after separation of
PCR fragments in ethidium bromide-stained 2% agarose gels, followed
by direct visualization under ultraviolet light. As the −374T>A poly-
morphism is within the region where the 63-bp deletion occurs, the
ins/del heterozygotes cannot be homozygotes or heterozygotes for the
−374T>A polymorphism. These subjects can only have the T or the A
allele in the −374 nucleotide site, so they were deﬁned as having the
T/del or the A/del genotype.
In order to improve genotyping accuracy, samples with known
genotypes were used in each run and genotyping was performed by
laboratory personnel who were unaware of clinical status of the
subjects. The minimal genotyping success rate was 97.4%.
2.4. Statistical analysis
Continuous data are reported as mean±SD, for variables with
normal distribution, or as median (interquartile range), for variables
with skewed distribution. Categorical variables are reported as abso-
lute numbers and percentages. Kolmogorov–Smirnov test was used to
Table 1
Baseline characteristics of heart failure (HF) patients.
Characteristics Caucasian-Brazilians
(n=196)
African-Brazilians
(n=77)
p
Age (years) 62±13 60±11 0.322
Male sex (%) 131 (66.8) 54 (70.1) 0.704
HF etiology
Ischemic (%) 91 (46.4) 25 (32.5) 0.050
Idiopathic (%) 68 (34.7) 23 (29.9) 0.536
Hypertensive (%) 43 (21.9) 31 (40.3) 0.004
Left ventricular ejection
fraction (%)
32±8 31±8 0.736
New York Heart Association
functional classes I and II (%)
156 (79.6) 56 (72.7) 0.287
Type 2 diabetes mellitus (%) 72 (36.7) 20 (26.0) 0.121
Creatinine (mg/dL) 1.2 (1.0–1.5) 1.3 (1.0–1.8) 0.422
HF medication
Beta-blockers (%) 173 (88.3) 64 (83.1) 0.351
ACE inhibitor (%) 170 (86.7) 71 (92.2) 0.449
Values are expressed as mean±SD, median (interquartile range) or n (%). p-Values
were computed by chi-square, Student t test or Mann–Whitney for comparison
between Caucasian- and African-Brazilians. Signiﬁcant p-value is shown in bold.
ACE, angiotensin-converting enzyme.
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were compared by the Student t test or Mann–Whitney U test and
categorical variables by the chi-square test or Fisher Exact test, as ap-
propriate. Allele frequencies were determined by gene counting and
departures from Hardy–Weinberg equilibrium (HWE) were veriﬁed
using the chi-square test. The chi-square test was also used to com-
pare the allele and genotype frequencies among groups of subjects.
The association of RAGE gene polymorphisms with HF susceptibility
was also evaluated by logistic regression analysiswith estimates of odds
ratios (ORs) and 95% conﬁdence intervals (CI) whenever required to
control for confounders. For the analysis of prognosis, Kaplan–Meier
survival curves were constructed from the date of entry at the outpa-
tient clinic to the last registry of follow-up or death and compared by
the log-rank statistics.
Haplotype frequencies were estimated by a Bayesian method using
PHASE program, version 2.1 (Stephens and Scheet, 2005; Stephens et
al., 2001). Carriers of either the T/del or A/del genotypes were excluded
from haplotype analysis. We also used the PHASE program to compare
the distribution of different RAGE haplotypes between groups of
subjects (cases and controls), computing p-values by a case–control
permutation test with 1000 random replicates. Moreover, individual
haplotypes were compared between cases and controls by Z-score,
using PEPI program version 4.0 (Abramson and Gahlinger, 2002). The
linkage disequilibrium between −374T>A and −429T>C polymor-
phisms was calculated according to the Lewontin formulae (Lewontin,
1988) and expressed in terms of D′.
All statistical analyses were stratiﬁed by self-reported ethnicity
and were done using SPSS statistical package (version 16.0). In addi-
tion to the main analysis considering the group of HF patients as a
whole, all data were also analyzed stratifying by diabetes. A p-value
b0.05 was considered to be statistically signiﬁcant.
Among Caucasian-Brazilians, the power to detect an association of
−374T>A and−429T>C polymorphisms with HF was 94% and 93%,
respectively, at a signiﬁcance level of 0.05 for an OR of 2.0, considering
the carriership of the minor alleles as the risk factor. For African-
Brazilians, our study had a power of 79% and 67% for the −374T>A
and −429T>C polymorphisms, respectively, to detect an OR of 2.5,
also considering the carriership of the minor alleles as the risk factor.
Power calculations were done with PEPI program (Abramson and
Gahlinger, 2002).
3. Results
3.1. Clinical and demographic characteristics
Clinical and demographic characteristics of HF patients are summa-
rized according to self-reported ethnicity (Table 1). In both groups, HF
patients were predominantly middle-aged male, with moderate to
severe left ventricular dysfunction and in New York Heart Association
class I or II. African-Brazilian HF patients had a higher prevalence of hy-
pertensive etiology, whereas Caucasians had predominantly ischemic
etiology. Themajority of patientswere taking standard pharmacological
therapy for HF, including beta-blockers and angiotensin-converting
enzyme inhibitors. Most healthy subjects (control group) were male
(approximately 70% in both ethnic groups), with a similar mean age
(46±12 years and 47±10 years in Caucasian- and African-Brazilians,
respectively), being signiﬁcantly younger than HF patients (pb0.001).
3.2. Association between RAGE polymorphisms and susceptibility to
heart failure
The genotype frequencies were in agreement with those predicted
by the Hardy–Weinberg equation for all RAGE polymorphisms in both
HF patients and healthy blood donors, except for the 63-bp ins/del poly-
morphism in African-Brazilian HF patients, for which there was a lower
frequency of heterozygotes than expected (expected frequency=3.9%vs observed frequency=1.3%, pb0.001). Among healthy blood donors,
the genotype and allele frequencies of the 63-bp ins/del polymorphism
in Caucasian-Brazilians were signiﬁcantly different from those of
African-Brazilians (pb0.01) (Table 2).
As shown in Table 2, the frequency of carriers of the del allele was
marginally lower in HF patients as compared to blood donors among
African-Brazilians (2.6% vs 12.2%, p=0.051) and the del allele
revealed to be associated with HF susceptibility (OR 0.19, 95% CI
0.04–0.92, p=0.039). Even after controlling for age and gender,
the del allele remained as an independent factor associated with a
decreased risk of having HF in African-Brazilians (OR 0.16, 95% CI
0.02–0.96, p=0.046). In relation to the −374T>A and −429T>C
polymorphisms, there were no statistically signiﬁcant differences
in genotype and allele frequencies between blood donors and HF
patients in either Caucasian- or African-Brazilians. These analyses
were also carried out assuming three different genetic models for
the minor alleles (dominant, recessive and codominant) and no as-
sociation of these polymorphisms with HF was suggested (data not
shown).
3.3. Association between RAGE polymorphisms and prognosis of heart
failure
Clinical follow-up data were collected for all enrolled HF patients.
During a median follow-up of approximately 38 months (range
1–116), 92 patients had died (33.2%), being 64 Caucasian- and 28
African-Brazilians. Fig. 1 depicts the Kaplan–Meier survival curves for
all-cause mortality in Caucasian- and African-Brazilians according to
the 63-bp ins/del, −374T>A and −429T>C polymorphisms in RAGE
gene, respectively. Analyses showed a similar survival proﬁle in both
ethnic groups for all-cause death for the −374T>A and −429T>C
polymorphisms. Among African-Brazilians, carriers of the del allele
had lower event-free survival (log-rank p-value=0.007).
3.4. Association between RAGE haplotypes and heart failure
Next, using a Bayesian method to estimate the frequency of differ-
ent haplotypes composed of the−374T>A and−429T>C polymor-
phisms, we sought to investigate if a speciﬁc haplotype would be
associated with HF susceptibility or progression. The −374T>A and
−429T>C polymorphisms were almost in complete linkage disequi-
librium among Caucasian-Brazilians (D′=−0.99 in both blood
donors and HF patients) and African-Brazilians (D′=−0.99 in
blood donors and D′=−0.98 in HF patients). As can be seen in
Table 2
Frequency of RAGE polymorphisms in healthy blood donors and heart failure (HF) patients.
Polymorphisms Caucasian-Brazilians (n=456) African-Brazilians (n=151)
Blood donors HF patients p Blood donors HF patients p
63-bp ins/del n=260 n=196 n=74 n=77
Genotypes ins/ins 254 (97.7) 188 (95.9) 0.416 65 (87.8) 75 (97.4) 0.008
ins/del 6 (2.3) 8 (4.1) 9 (12.2) 1 (1.3)
del/del 0 0 0 1 (1.3)
Alleles ins 0.99 0.98 0.420 0.94 0.98 0.123
del 0.01 0.02 0.06 0.02
−374T>A n=260 n=194 n=74 n=76
Genotypes TT 121 (46.5) 73 (37.6) 0.203 38 (51.3) 44 (57.9) 0.077
TA 100 (38.5) 92 (47.5) 21 (28.4) 27 (35.5)
AA 33 (12.7) 21 (10.8) 6 (8.1) 4 (5.3)
T/del 4 (1.5) 5 (2.6) 5 (6.8) 0
A/del 2 (0.8) 3 (1.5) 4 (5.4) 1 (1.3)
Alleles T 0.67 0.64 0.328 0.73 0.76 0.682
A 0.33 0.36 0.27 0.24
−429T>C n=257 n=196 n=74 n=75
Genotypes TT 190 (74.0) 146 (74.5) 0.691 61 (82.4) 58 (77.3) 0.691
TC 60 (23.3) 47 (24.0) 12 (16.2) 15 (20.0)
CC 7 (2.7) 3 (1.5) 1 (1.4) 2 (2.7)
Alleles T 0.86 0.87 0.780 0.90 0.87 0.485
C 0.14 0.13 0.10 0.13
Genotype and allele frequencies are shown as number, n (%) of subjects. p-Values were calculated by chi-square or Fisher Exact test comparing blood donors vs. HF patients within
each ethnic group. Signiﬁcant p-value is shown in bold.
10 C.R. Cohen et al. / Gene 510 (2012) 7–13Table 3, the −374T/−429T haplotype was the most frequent one in
all groups of subjects. The haplotype frequencies in HF patients
were very similar to those observed in healthy blood donors, in
both ethnic groups. We further analyzed mortality outcome in HF
patients according to the carriership of at least one minor allele con-
sidering the −374T/−429T haplotype as the reference. As depicted
in Fig. 2, no association of haplotypes with all-cause mortality was
observed in Caucasian- and African-Brazilians.Fig. 1. Kaplan–Meier survival curves for all-cause mortality in Caucasian- (A to C) and A
polymorphisms in RAGE gene, respectively.3.5. Association between RAGE polymorphisms and heart failure in
diabetic and non-diabetic patients
Taking into account that there may be an interaction between
diabetes and RAGE gene polymorphisms on the development and
progression of HF, we repeated all analyses stratifying by diabetes
(see supplementary material available online). All diabetic patients
had type 2 diabetes. Among Caucasian-Brazilians, there was a trendfrican-Brazilians (D to F) according to the 63-bp ins/del, −374T>A and −429T>C
Table 3
Haplotype frequencies of RAGE polymorphisms in healthy blood donors and heart failure (HF) patients.
Haplotype Caucasian-Brazilians (n=439) Z-score p African-Brazilians (n=141) Z-score p
Blood donors (n=251) HF patients (n=188) Blood donors (n=65) HF patients (n=76)
Frequencies S.E. Frequencies S.E. Frequencies S.E. Frequencies S.E.
−374T/−429T 0.5281 0.0008 0.5039 0.0029 0.41 0.685 0.6465 0.0017 0.6378 0.0068 0.00 >0.999
−374T/−429C 0.1472 0.0008 0.1354 0.0011 0.21 0.832 0.0997 0.0017 0.1284 0.0054 0.27 0.789
−374A/−429T 0.3245 0.0008 0.3604 0.0029 0.68 0.494 0.2535 0.0017 0.2331 0.0049 0.08 0.933
−374A/−429C 0.0002 0.0008 0.0003 0.0011 0.00 >0.999 0.0003 0.0017 0.0006 0.0025 0.00 >0.999
Permutation test p-value 0.529 0.733
Haplotype frequencies are shown as percentage of a given number (n) of subjects. PHASE programwas used to estimate the haplotype frequencies and to compare blood donors vs. HF
patients, computing p-values by a case–control permutation test. Individual haplotypes were compared between blood donors and HF patients using Z-score in PEPI program.
S.E., standard error.
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del polymorphism) in diabetic HF patients as compared to healthy
blood donors (Supplementary Table S1). Likewise, the del allele
tended to be more frequent among HF patients with diabetes in com-
parison to healthy blood donors and HF patients without diabetes. On
the other hand, among African-Brazilian subjects (Supplementary
Table S2), the frequency of carriers of the del allele was lower in HF
patients than in healthy blood donors.
As shown in Supplementary Table S3, the haplotype frequencies in
Caucasian-Brazilian HF patients were similar to those observed in
healthy blood donors of the same ethnic group, regardless of the pres-
ence of diabetes. However, among African-Brazilians, haplotypes
containing either the −374A or −429C allele were more frequent
among HF patients without diabetes than in those with diabetes
(Supplementary Table S4). In fact, carriership of at least oneminor allele
was found to be associated with diabetes among African-Brazilian HF
patients (OR 0.31, 95% CI 0.11–0.89, p=0.029). However, after control-
ling for clinical variables that were also associated with diabetes in the
univariate analysis (percutaneous transluminal coronary angioplasty/
stent, peripheral vasculopathy, left ventricular end-diastolic volume,
diastolic blood pressure, serum triglycerides and potassium levels),
the carriership of at least one minor allele did not remain associated
with diabetes (OR 0.32, 95% CI 0.04–2.96, p=0.319).
In relation to survival proﬁle for all-cause mortality stratiﬁed by
diabetes (Supplementary Figs. S1 to S3), the only statistically signiﬁ-
cant ﬁnding was observed for the 63-bp ins/del polymorphism
(Supplementary Fig. S2) among non-diabetic African-Brazilians
(log-rank p-value=0.017).Fig. 2. Kaplan–Meier survival curves for all-cause mortality in Caucasian- (A) a4. Discussion
In the present study, no association of the−374T>A and−429T>C
polymorphisms in RAGE gene with the susceptibility and prognosis of HF
was observed in Caucasian- andAfrican-Brazilian outpatientswith systol-
ic dysfunction. However, among African-Brazilians, the del allele of the
63-bp ins/del polymorphism was associated with a lower risk of HF and
carriers of this allele had a higher mortality rate than homozygotes for
the ins allele. Although there is some degree of genetic admixture in
Southern Brazilian population, the prevalence of the studied polymor-
phisms was similar to that previously reported (Hudson et al., 2001a;
Kalea et al., 2009; Picheth et al., 2007; Santos et al., 2005; Torres et al.,
2012). Notably, the del allele (63-bp ins/del polymorphism) seems to be
more frequent in non-Caucasians than in Caucasians (Hudson et al.,
2001a; Poon et al., 2010; Santos et al., 2005; Torres et al., 2012).
Since the 63-bp ins/del, the −374T>A and the −429T>C poly-
morphisms of the promoter region were described as affecting the
RAGE gene expression in 2001 (Hudson et al., 2001a), several studies
analyzed their role in the pathogenesis of diverse cardiovascular dis-
eases in both diabetic and non-diabetic patients (Aydoğan et al.,
2012; Boiocchi et al., 2011; Falcone et al., 2004, 2005, 2007, 2008;
Hudson et al., 2001b; Kirbis et al., 2004; Lu et al., 2008; Peng et al.,
2009; Pettersson-Fernholm et al., 2003; Picheth et al., 2007; Poon et
al., 2010; Santos et al., 2005; Shim et al., 2007; Yoon et al., 2007). In
most of these studies, the −374A allele was found to be protective
against the development and/or severity of ischemic heart disease,
coronary artery disease and acute myocardial infarction, including
two previous studies in Brazilians with type 2 diabetes (Picheth etnd African-Brazilians (B) according to the number of minor alleles carried.
12 C.R. Cohen et al. / Gene 510 (2012) 7–13al., 2007; Santos et al., 2005). However, we failed to demonstrate an
association of the −374T/A polymorphism with the presence of HF
itself and with mortality in HF patients.
These discrepancies may be related to the heterogeneous clinical
and biological proﬁles of the populations enrolled in the different
studies, including the deﬁnition of outcomes (composite or only one),
exclusion criteria, glucose metabolism status and sample size. In fact,
the studies that failed to show a role of the −374T>A polymorphism
in heart disease were mainly conducted on subjects of oriental
ethnicity. The −429T>C polymorphism has also been studied along
with−374T>A; however, no association has been reported with car-
diovascular disease (Hudson et al., 2001b; Kirbis et al., 2004; Lu et al.,
2008; Pettersson-Fernholm et al., 2003; Poon et al., 2010; Santos et al.,
2005; Shim et al., 2007; Yoon et al., 2007), as also observed in the
present study.
In a study on Chinese type 2 diabetic patients with diabetic
nephropathy, patients were followed for 8 years for the development
of cardiovascular events and survival (Poon et al., 2010). It was
observed that subjects with at least one minor allele of the three
RAGE polymorphisms had a lower incidence of ischemic heart disease
and HF as compared with those having no minor allele (homozygous
for major alleles). In the present study, the frequency of carriership of
at least one minor allele was similar in different groups of subjects.
However, in line with the ﬁndings of Chinese study, the carriership
of del allele (63-bp ins/del polymorphism) was less frequent in HF
patients as compared to healthy blood donors, which suggests a
protective role of this polymorphism for the development of HF.
Moreover, Poon et al. (2010) found that patients with the ins/del
genotype had a higher event-free survival rate than homozygotes for
the ins allele. In that study, the primary endpoint was a composite
one that consisted of cardiovascular death and congestive heart failure,
among others. In our study, on the contrary, African-Brazilian carriers of
the del allele had a lower survival rate. Nevertheless, the protective role
of del allele observed in the Chinese study (Poon et al., 2010) was not
independent of other risk factors and in our study there were only
two carriers of del allele among African-Brazilian HF patients, one of
whom died in the ﬁrst months of follow-up. Thus, the importance of
the 63-bp ins/del polymorphism in the manifestation of clinical events
remains unsolved. In addition, none of the polymorphisms studied in
Chinese patients had a signiﬁcant effect on all-causemortality or cardio-
vascular mortality (Poon et al., 2010), as also observed in our study for
the−374T>A and−429T>C polymorphisms.
In our study, the genotype frequencies of the 63-bp ins/del polymor-
phism were not in HWE in African-Brazilian HF patients. Departures
from HWE are attributable to population stratiﬁcation, non-random
mating, evolutionary forces and also genotyping errors. Traditionally,
genotyping errors are assumed as the most common cause of deviation
from HWE (Hosking et al., 2004). However, some authors state that in
association studies, in the presence of a gene–disease association, HWE
may be violated in individuals with the disease, because alleles within
genotypes that confer greater susceptibility are represented in the sam-
ple at disproportionally high rates. So, the violation of HWE in the case
group may be due to a real association, while the control group is in
equilibrium (Nielsen et al., 1999). Our results are in agreement with
this assumption, since the genotype frequencies were in HWE in
African-Brazilianblood donors, andboth groups of subjects had identical
sample size. It is unlikely that genotyping errors have occurred, because
personnel in laboratory were blinded to the characteristics of the sub-
jects. After the preliminary analysis, genotyping of all the samples of
African-Brazilian HF patients was repeated, generating the same results.
Nevertheless, the results observed in our study regarding the 63-bp ins/
del polymorphism in African-Brazilians should be viewed with caution
due to the small sample size (which contributes to low statistical
power) and the low frequency of the del allele. These preliminary ﬁnd-
ings highlight the need of evaluating the 63-bp ins/del polymorphism in
other African-derived populations, with appropriate sample size.It is well described that glycemic status inﬂuences the relationship
between RAGE polymorphisms and clinical outcomes (Engelen et al.,
2010; Falcone et al., 2008; Kucukhuseyin et al., 2009; Picheth et al.,
2007). In a Brazilian study, the −374AA genotype was associated
with decreased severity of coronary artery disease only in the group
of patients with type 2 diabetes. Among non-diabetic subjects, this
protective effect was not observed (Picheth et al., 2007). Accordingly,
the −374AA genotype was found to be a protective factor for cardiac
events in non-diabetic Italians with coronary artery disease (Falcone
et al., 2008). In contrast with these studies, the −374A allele was
found to be a risk factor for coronary artery disease in Turkish patients
with diabetes (Kucukhuseyin et al., 2009). Moreover, in two Dutch
population-based cohort studies, the −374AA genotype was protec-
tively associatedwith blood pressure and arterial stiffness in individuals
with normal glucosemetabolism, whereas in individuals with impaired
glucosemetabolismor type 2 diabetes, the samegenotypewas adverse-
ly associated with these variables (Engelen et al., 2010).
In the present study, although not statistically signiﬁcant, the differ-
ences in the frequency of RAGE polymorphisms were found in the com-
parison between HF patients with type 2 diabetes and healthy blood
donors. The signiﬁcative ﬁndings were observed for the 63-bp ins/del
polymorphism. The causal mechanism for these contrasting effects is
still unknown, but as already suggested (Engelen et al., 2010),metabolic
abnormalities in response to hyperglycemia seem to inﬂuence the
effects of RAGE polymorphisms. Thus, diabetes is a potential modiﬁer
factor that should be considered in the analyses of the relationship
between RAGE polymorphisms and cardiac outcomes.
Some limitations of our study should be considered. First, the retro-
spective design used to the analysis of susceptibility of HF does not
allow us to rule out the possibility that theremight have been a survival
bias with regard to the 63-bp ins/del polymorphism. In our study, the
survival analysis suggested that the African-Brazilian carriers of del al-
lele were more likely to die. If this would be true, the lower frequency
of del carriers in African-Brazilian HF patients as compared to healthy
blood donors could be a consequence of the highest mortality of del
carriers who have HF. It is also possible that the positive ﬁndings of
the 63-bp ins/del polymorphism are due to a type 1 error, since there
is almost three times more Caucasians- than African-Brazilians in our
study sample. Another aspect that deserves consideration is the fact
that HF patients are older than healthy blood donors. If young subjects
who are prone to develop HF in the future are included in the control
group, this could lead to a dilution of positive results. Moreover, we
did not measure the sRAGE serum levels in our patients, and thus, we
could not establish a relationship between the three RAGE gene
polymorphisms and sRAGE levels. Finally, as mentioned before, HF is a
multifactorial syndrome that remains a major cause of morbidity and
mortalityworldwide. For this reason, studies focused on the pathophys-
iology of this condition require a more extensive study population.
Considering the small number of patients evaluated, our ﬁndings are
only preliminary and require to be replicated in other studies.
In conclusion, the 63-bp ins/del, the−374T>A and the−429T>C
polymorphisms in the RAGE gene were not associated with susceptibil-
ity of HF and all-cause mortality in Caucasian-Brazilian HF patients.
However, among African-Brazilians, the del allele (63-bp ins/del
polymorphism) was associated with a decreased risk of HF. To our
knowledge, as this is the ﬁrst study aimed to investigate the association
of RAGE gene polymorphisms with HF, their role in the pathogenesis of
HF cannot yet be elucidated. Taking into account the importance of
RAGE for cardiac function and its potential use as a biomarker of
prognosis in HF patients, further studies are needed to explore and
clarify these associations.
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